Subject index

SUBJECT INDEXNote: Numbers in boldface indicate volume; numbers in lightface indicate page numbers.

Ablative therapyfor Barrett’s esophagus and early esopha-

geal cancer, 1:241–245, 252–257, 258–263

for hepatocellular carcinoma, 1:13–15,17–18

Absolute risk reduction (ARR), inevidence-based studies, 1:60–61

Academic medical centers, integra-tion of digestive health servicesin, 1:145–151

Academic physician-scientists,challenges of, 1:153–155

Acetic acid injection, for hepatocellu-lar carcinoma, 1:14

Acetylcholinesterase inhibitors,for postoperative ileus, 1:76

Acid, and laryngeal injury in GERD,1:334–335

Adefovir dipivoxil, for chronic hepati-tis B infection, 1:418

Adenocarcinoma, esophagealBarrett’s esophagus and, 1:83–84, 241,

252, 256early, endoluminal therapy for, 1:241–

245, 252–257GERD and, 1:81, 83–84incidence of, 1:253

Adenocarcinoma, pancreatic, rapidendoscopic secretin stimulationtest for, 1:397–403

Adenocarcinoma, prostate, choles-tatic jaundice as paraneoplasticmanifestation of, 1:480–483

Adenomas, colorectalcolorectal cancer risk factors in patients

with, 1:415diminutive, predictive value of, 1:195–

201family history of, as indication for cancer

screening, 1:69–70, 96–102five-year interval in screening for, in pa-

tients with family history of can-cer, 1:310–314

NSAIDs and reduced incidence of,1:310–314, 415–420

as predictor of advanced proximal neo-plasia, 1:103–110

Adenoma-to-carcinoma sequence,1:310

Adenomatous polyposis coli(APC) mutations, in colorec-tal cancer, fecal testing for,1:377–383

ADL8-2698 (Alvimopan), for postop-erative ileus, 1:75

�-Adrenergic receptor antagonistsfor diarrhea-predominant irritable bowel

syndrome, 1:111–121for postoperative ileus, 1:72, 76–77

�-Adrenergic receptor antagonists, for post-operative ileus, 1:72, 76–77

African iron overload, 1:247Age, maternal, and pediatric-onset

Crohn’s disease, 1:303–309Alanine transaminase (ALT)

in autoimmune pancreatitis, 1:454, 455,457, 460

in mushroom-induced hepatitis, 1:392–396

Alcohol abuseand hepatocellular carcinoma, 1:10and tumefactive chronic pancreatitis,

1:129–135, 421Alkaline phosphatase

in autoimmune pancreatitis, 1:454, 455,457, 460

in prostate cancer, 1:480–483Alosetron, for irritable bowel syndrome,

1:157Alpha-4 integrin, in Crohn’s disease,

therapy targeting, 1:417Amanita phalloides poisoning,

recovery from without liver trans-plantation, 1:392–396

Ambulation, early, in postoperativeileus, 1:75

Ambulatory esophageal and pha-ryngeal pH monitoring, inGERD patients with laryngealcomplaints, 1:333, 338–340

American Gastroenterological As-sociation, new journal of,1:1–2

5-Aminosalicylic acid (me-salamine)

for Crohn’s disease, versus budesonide,1:122–128

delivery systems for, 1:3–4, 36–43once daily versus conventional dosing of,

1:170–173optimal dosing of, 1:3–4, 36–43for ulcerative colitis, 1:3–4, 36–43,

170–173Amitriptyline, for irritable bowel syn-

drome, 1:156, 225–226Ampicillin, hemorrhagic colitis associ-

ated with, Klebsiella oxytoca in,1:370–376

Anesthesia, and postoperative ileus,1:72, 73, 74

Antacids, for GERD, 1:81–82Antiandrogen agents, for hepatocel-

lular carcinoma, 1:16, 18Antibiotic resistance, in Helicobacter

pylori infection, 1:273–278Antibiotic-associated hemor-

rhagic colitis (AAHC),Klebsiella oxytoca in, 1:370–376

Anticarbonic anhydrase-II (ACA-II), in autoimmune pancreatitis,1:453, 454, 455, 459

Anticholinergic agents, with endo-scopic clip closure of esophagealperforation, 1:46–47, 49

Antidepressantsand colonic sensorimotor function,

1:211–218gender-specific responses to, 1:157for irritable bowel syndrome, 1:155–

159, 219–228Antiestrogen agents, for hepatocellu-

lar carcinoma, 1:16, 18Antihistamines, for eosinophilic esoph-

agitis, 1:436Antimicrobial susceptibility test-

ing, in Helicobacter pylori infec-tion, 1:273–278

Antimitochondrial antibodies, pos-itive, liver biopsy in patientswith, 1:89–95

Antinuclear antibodies (ANAs), inautoimmune pancreatitis, 1:453,454, 455, 459–460

Antireflux surgeryfor cancer prevention, 1:83–84cost-effectiveness of, 1:84–85, 328–332endoscopic, 1:85–86gastric accommodation and emptying

after, evaluation of, 1:264–272for GERD, versus medical therapy, 1:81–

88, 328–332laparoscopic, 1:82, 84, 328–332safety and side effects of, 1:84

APC mutations, in colorectal cancer,fecal testing for, 1:377–383

Argon beam plasma coagulation(ABPC), for Barrett’s esopha-gus, 1:241–242, 258–263

Ascites, in cirrhosis, evidence-based stud-ies of management of, 1:474–479

Aspartate transaminase (AST)in autoimmune pancreatitis, 1:454, 455,

457, 460in mushroom-induced hepatitis, 1:392–

396Aspirin

benefit-to-risk ratio with, 1:415for colorectal cancer prevention, 1:415–

416enteric coated, ulcerative ileitis induced

by, 1:160–169and reduced incidence of adenomas,

1:310–314, 415–420ulcer bleeding with ongoing therapy,

prevention of, 1:416

Autoimmune pancreatitis, 1:133–134

association with other autoimmune disor-ders, 1:421–422, 453

biliary system involvement in, 1:421,453–464

biopsies in, 1:454, 457, 460–461clinical characteristics of, 1:421diagnosis of, 1:454diagnostic characteristics of, 1:453histologic findings in, 1:457, 460imaging in, 1:454, 456, 457, 458pathology of, 1:422primary and secondary, 1:422simplification and consistency in field of,

1:421–422terms for, 1:421treatment of, 1:454, 457–459

Autonomic function, in irritablebowel syndrome, 1:111–121

Azathioprinefor eosinophilic esophagitis, 1:434with infliximab, for Crohn’s disease,

1:417

Barcelona Clinic Liver Cancer(BCLC), hepatocellular carci-noma classification of, 1:11

Barrett’s esophagusargon beam plasma coagulation for,

1:241–242, 258–263and cancer risk, 1:83–84, 241, 252, 256clinical significance of, 1:241endoluminal therapy for, 1:241–245,

252–257, 258–263endoscopic mucosal resection and photo-

dynamic therapy for, 1:241–245,252–257

GERD and, 1:83–84Bile acids, and laryngeal injury in

GERD, 1:334–335Bile ducts

in autoimmune pancreatitis, 1:421,453–464

in hepatolithiasis patients, prostaglandinE receptors in, 1:285–296

Biliary complications, in donors forliving donor liver transplantation,endoscopic management of,1:183–188

Biliary stenting, endoscopic, in donorsfor living donor liver transplanta-tion, 1:183–188

Bilirubinin GERD patients with laryngeal com-

plaints, 1:335in mushroom-induced hepatitis, 1:392–

396in prostate cancer, 1:480–483

Bone health, in inflammatory boweldisease, 1:348–349, 465–473

Bowel obstruction, postoperative.See Ileus, postoperative

Budesonidefor Crohn’s disease, versus mesalamine,

1:122–128for eosinophilic esophagitis, 1:434, 436

Buspirone, and colonic sensorimotorfunction, 1:211–218

C282Y mutation of HFE geneheterozygosity for, and hepatocellular

carcinoma, 1:246–248, 279–284homozygosity for, normal ferritin levels

in patients with, 1:388–391

Cancer of the Liver Italian Pro-gram (CLIP), hepatocellularcarcinoma classification of, 1:11

CARD15 (NOD2) gene mutationsin Crohn’s disease, 1:5–9discovery of, impact of, 1:5influence on clinical presentation and

natural history, 1:6–7risk conferred by inheritance of, 1:5–6screening for, 1:8and treatment response, 1:7–8

Catecholamines, in postoperative ileus,1:72

CD4� and CD8� cells, in autoim-mune pancreatitis, 1:454, 457,461–462

Celiac diseasehistologic features of, fluctuating trans-

glutaminase autoantibodies and,1:356–362

in North American community, trendsin identification and clinical fea-tures, 1:19–27

Centers for Medicare and Medic-aid Services, 1:237–239

Cetuximab, potential use in gastric can-cer, 1:439, 444

Chemoembolization, for hepatocellu-lar carcinoma, 1:15–16, 18

Chemotherapy, for hepatocellular carci-noma, 1:16

Chest pain, with exercise-induced reflux,1:346

ChildrenCrohn’s disease in, sex-specific risks for,

1:303–309at risk for celiac disease, fluctuating

transglutaminase autoantibodiesin, 1:356–362

Cholangitischronic proliferative, prostaglandin E

receptors in, 1:285–296primary sclerosing, pancreatitis with,

1:421–422, 453, 459, 462–463Cholecystokinin, endoscopic pancreatic

function test with, 1:189–194

versus secretin stimulation test, 1:397–403

Cholestasis, pruritus in, 1:249–251,297–302

Cholestatic biochemical profile,liver biopsy in patients with,1:89–95

Cholestatic jaundice, paraneoplastic,in prostate cancer, 1:480–483

Chromoendoscopy, methylene blue-aided, in colorectal cancer, 1:416

Cigarette smoking, and risk of colo-rectal cancer, in postmenopausalwomen, 1:202–210

Cirrhosisascites in, evidence-based studies of man-

agement of, 1:474–479and hepatocellular carcinoma, 1:10–13primary biliary

common signs and symptoms of, 1:89liver biopsy for diagnosis of, 1:89–95pancreatitis with, 1:421–422, 453pruritus in, 1:249–251, 297–302

Cisapride, for postoperative ileus, lack ofbenefit and potential for harmwith, 1:76

Citalopram, for irritable bowel syn-drome, 1:156–157

Clarithromycin, for Helicobacter pyloriinfection, microbial susceptibilityto, 1:273–278

Clinical Gastroenterology andHepatology, editorial on startof, 1:1–2

Clinical practice guidelinesapplication to patients, 1:326–327assessing design of, 1:322–325for cirrhotic ascites, 1:477–478definition of, 1:322evidence-based approach to, 1:322–327interpreting results of, 1:325–326for irritable bowel syndrome, 1:322–327

Clinical research, 2002-2003, reviewof, 1:415–420

Clinical Research EnhancementAct, 1:153

Clip, endoscopic, for closure of matureesophageal perforation with fistu-lae, 1:44–50

Clonidine, for diarrhea-predominant irri-table bowel syndrome, 1:111–121

Codes, for gastrointestinal practice, up-date on, 1:237–239

Cohort studies, 1:230Colectomy, recurrence of symptomatic

Crohn’s disease after, evidence-based studies of, 1:229–236

Colitisantibiotic-associated hemorrhagic, Kleb-

siella oxytoca in, 1:370–376

488 SUBJECT INDEX CLINICAL GASTROENTEROLOGY AND HEPATOLOGY Vol. 1, No. 6

ulcerative. See Ulcerative colitis(UC)

Collaborative health care model,for irritable bowel syndrometreatment, 1:423–424, 446–452

Colonic sensorimotor functioneffects of venlafaxine, buspirone, and

placebo on, 1:211–218selective serotonin reuptake inhibitors

and, 1:155–159Colonoscopy

conventional, as gold standard for cancerdiagnosis, 1:138–139

cost-effectiveness of, 1:404–413family history of adenomas as indication

for, 1:69–70, 96–102five-year interval between, for patients

with family history of colorectalcancer, 1:310–314

follow-up, findings in flexible sigmoidos-copy indicating, 1:103–110

ileoscopy with, drug-induced ulcerativeileitis encountered in, 1:160–169

sedation for, propofol versus midazolam/fentanyl, 1:425–432

virtual (computed tomography), evi-dence-based studies of, 1:136–144

Colorectal canceraspirin and prevention of, 1:415–416cigarette smoking and risk in postmeno-

pausal women, 1:202–210cost-effectiveness of screening strategies

for, 1:404–413diagnostic tests for, evidence-based stud-

ies of, 1:136–144exercise and, 1:350–351family history of, five-year interval be-

tween colonoscopies in patientswith, 1:310–314

fecal multiple molecular tests for,1:377–383

flexible sigmoidoscopy findings as predic-tor of, 1:103–110, 195–201

lifetime prevalence of, 1:310methylene blue-aided chromoendoscopy

in, 1:416pretest probability of, 1:136–138research in 2002-2003, review of,

1:415–416risk factors in patients with polyps,

1:415screening for, family history of adenomas

as indication for, 1:69–70, 96–102

Competency assessment, by faculty,versus knowledge base evaluationof residents, 1:64–68

Computed tomographyin autoimmune pancreatitis, 1:454, 457,

458, 459colonoscopy with, evidence-based studies

of, 1:136–144in hepatocellular carcinoma, 1:11, 12

Concealed allocation, in evidence-based studies, 1:58–59

Confidence intervals, 1:61Conflict management, by academic

physician-scientists, 1:153–155Confounding, 1:235Constipation, exercise and, 1:349–350Corticosteroid therapy, and fracture

risk, 1:465–473Cost-effectiveness analysis (CEA),

of colorectal cancer screeningstrategies, 1:404–413

Cough, chronic, in GERD, 1:333CPT codes, 1:237–239Crohn’s disease (CD)

CARD15 gene mutations in, 1:5–9clinical presentation of, 1:6–7versus drug-induced ileitis, 1:166–167exercise effects in, 1:348–349fracture risk in, 1:465, 471genetic screening in, 1:8infliximab (anti-tumor necrosis factor-�

therapy) for, 1:7–8, 416–417natalizumab (anti-alpha 4 integrin ther-

apy) for, 1:417natural history of, 1:6–7pancreatitis with, 1:453pediatric-onset, sex-specific risks for,

1:303–309recurrence after surgery, evidence-based

studies of, 1:229–236steroid-dependent, budesonide versus me-

salamine in, 1:122–128treatment response in, 1:7–8working model of, 1:5

Cryoshock syndrome, 1:15Cryotherapy, for hepatocellular carci-

noma, 1:15Cumulative incidence, 1:232–234Current procedure terminology

(CPT), 1:237–239Cyclooxygenase-2, in cholangitis,

1:285–296Cyclooxygenase-2 inhibitors

gastric effects of, evidence-based studiesof, 1:57–63

for postoperative ileus, 1:74–75ulcer bleeding with ongoing therapy,

prevention of, 1:416ulcerative ileitis induced by, 1:160–169

Cyclooxygenase inhibitors, for hep-atocellular carcinoma prevention,1:17

Cytokine(s)in non-alcoholic fatty liver disease, pio-

glitazone and, 1:386in postoperative ileus, 1:72

Cytotoxic therapy, for Barrett’s esoph-agus, 1:241–245

Dermatitis herpetiformis, in NorthAmerican community, 1:23–25

Desipramine, for irritable bowel syn-drome, 1:155–156

Diabetic dyspepsia, gastric accommo-dation and emptying in, evalua-tion of, 1:264–272

Diagnostic tests. See also specific diagnos-tic tests

accuracy of, quantification of, 1:142data from, likelihood ratios for maximiz-

ing utility of, 1:141–142evidence-based studies of, 1:136–144necessity of, 1:136–138new, comparison with gold standard,

1:138–139positive and negative predictive values

of, 1:140–141sensitivity of, 1:140–141specificity of, 1:140–141

Diarrhea, exercise and, 1:351–352Diarrhea-predominant irritable

bowel syndrome, clonidinefor, 1:111–121

Digestive Health Service Center(DHSC), 1:145–151

Digestive health services, integra-tion of, 1:145–151

Diminutive adenomas, predictivevalue of, 1:195–201

DNA, in colorectal cancer, fecal testing foralterations in, 1:377–383

Domperidone, for postoperative ileus,1:77

Donors, for living donor liver transplan-tation, endoscopic managementof biliary complications in,1:183–188

Double-blinding, in evidence-basedstudies, 1:58–59

Dreiling collection method, versusendoscopic collection, in pancre-atic function tests, 1:189–194

Dyspepsiafunctional, gastric mucosal mast cells in,

1:363–369gastric accommodation and emptying in

patients with, evaluation of,1:264–272

prevalence of, 1:363Dysphagia, in eosinophilic esophagitis,

endoscopic evaluation of, 1:433–437

November 2003 SUBJECT INDEX 489

Dysplasia, high-grade, Barrett’s esopha-gus with, endoluminal therapyfor, 1:241–245, 258–263

Dysplastic nodule, and hepatocellularcarcinoma, 1:11

Ear, nose, and throat (ENT) com-plaints, in GERD, cause andeffect association of, 1:333–344

Early ambulation, in postoperativeileus, 1:75

Early feeding, in postoperative ileus,1:75

Economic studies, evidence-based ap-proach to, 1:404–413

Electrolyte abnormalities, in post-operative ileus, 1:73

Endoluminal therapyfor Barrett’s esophagus and early esopha-

geal cancer, 1:241–245, 252–257, 258–263

candidates for, 1:243multimodal, 1:241–242

Endoscopic antireflux proce-dures, 1:85–86

Endoscopic biliary drainage(EBD), for autoimmune pancre-atitis, 1:454, 457

Endoscopic biliary stenting, in do-nors for living donor liver trans-plantation, 1:183–188

Endoscopic clip application, forclosure of mature esophageal per-foration with fistulae, 1:44–50

Endoscopic mucosal resection,with photodynamic therapy, forBarrett’s esophagus, 1:241–245,252–257

Endoscopic nasobiliary drainage,in donors for living donor livertransplantation, 1:183–188

Endoscopic pancreatic functiontest

for chronic pancreatitis, 1:189–194rapid secretin stimulation, 1:397–403

Endoscopic retrograde cholan-giography, for biliary compli-cations, in donors for living do-nor liver transplantation, 1:183–188

Endoscopic retrograde cholangio-pancreatography, in auto-immune pancreatitis, 1:453,454, 456, 457, 459–460, 462–463

Endoscopic ultrasound, of Barrett’sesophagus, 1:242–244

Endoscopy. See also specific endoscopic proce-dures

for biliary complication management, indonors for living donor livertransplantation, 1:183–188

in eosinophilic esophagitis, 1:433–437sedation for, propofol versus midazolam/

fentanyl, 1:425–432Enflurane, and postoperative ileus, 1:73Enteral feeding

early, in postoperative ileus, 1:75in necrotizing pancreatitis, 1:315–321

Enteric-coated acetylsalicylic acid(ECASA), ulcerative ileitis in-duced by, 1:160–169

Eosinophilic esophagitis, endoscopyin, 1:433–437

Epidermal growth factor recep-tor, expression, in gastric cancer,1:438–445

Epidural anesthesia, and reduction inpostoperative ileus, 1:72, 73, 74

Erythromycin, for postoperative ileus,lack of benefit and potential forharm with, 1:76

Esophageal cancerBarrett’s esophagus and, 1:83–84, 241,

252, 256early

combined endoscopic mucosal resec-tion with photodynamic therapyfor, 1:241–245, 252–257

endoluminal therapy for, 1:241–245,252–257

GERD and, 1:81, 83–84incidence of, 1:253

Esophageal function testingwith combined multichannel intralumi-

nal impedance and manometry,1:174–182

for laryngeal complaints in GERD,1:335

Esophageal perforationconservative management of, 1:44in endoscopy for eosinophilic esophagitis,

1:433–437mature with fistulae, endoscopic clip

application for closure of,1:44–50

Esophageal pH monitoring, inGERD patients with laryngealcomplaints, 1:335, 338–340

Esophageal specialized intestinalmetaplasia, endoluminal ther-apy for, 1:241–245

Esophagectomyfor Barrett’s esophagus, versus endolumi-

nal therapy, 1:241, 252–257,258–263

morbidity and mortality in, 1:241Esophagitis, eosinophilic, endos-

copy in, 1:433–437

Estrogen receptor antagonists, forhepatocellular carcinoma, 1:16

Evaluation of residents, knowledgebase versus faculty assessment,1:64–68

Evidence-based studiesaccurate and unbiased results of,

1:57–59alternative and effective treatments in,

1:62–63application to patients, 1:62, 142–143,

234–235, 326–327of ascites management in cirrhosis,

1:474–479benefits versus cost analysis in, 1:62of clinical practice guidelines, 1:322–

327concealed allocation in, 1:58of Crohn’s disease recurrence, after sur-

gery, 1:229–236cumulative incidence in, 1:232–234decisions based on, 1:63of diagnostic tests, 1:136–144double-blinding in, 1:58–59of economics, 1:404–413follow-up in, 1:59of gastric effects of COX-2 inhibitors,

1:57–63of gastrointestinal therapies, 1:57–63intention-to-treat analysis in, 1:59interpretation of results in, 1:140–142,

325–326of irritable bowel diagnosis and treat-

ment, 1:322–327magnitude of treatment benefit in, inter-

pretation of, 1:60–61of natural history, of gastrointestinal dis-

ease, 1:229–236nonstatistically significant results in, in-

terpretation of, 1:61outcome criteria for, 1:231precision of results in, 1:61randomized trial in, 1:57–58reproducibility of results of, 1:143series of articles on, 1:2significance of results in, 1:60statistical and clinical significance of re-

sults in, 1:59validity of study design in, 1:57of virtual (computed tomography)

colonoscopy, 1:136–144Exercise

and colorectal cancer, 1:350–351and constipation, 1:349–350and gastric acid production, 1:346–347and gastric cancer, 1:348and gastric emptying, 1:346–347and gastroesophageal reflux disease,

1:345–346and gastrointestinal bleeding, 1:351–

352


and gastrointestinal function and disease,1:345–355

and inflammatory bowel disease, 1:348–349

and liver disease, 1:352–353and peptic ulcer disease, 1:347–348

Expectation bias, 1:138External beam radiation therapy

(EBRT), for hepatocellular car-cinoma, 1:16–17

Family historyof adenomas, and colorectal cancer risk,

1:69–70, 96–102of colorectal cancer, five-year interval

between colonoscopies in patientswith, 1:310–314

Fatty liver disease, non-alcoholic,pioglitazone for, 1:384–387

Fecal multiple molecular tests, forcolorectal cancer, 1:377–383

Fecal occult blood tests (FOBT),for colorectal cancer, cost-effec-tiveness of, 1:404–413

Fedotozine, for postoperative ileus,1:77

“Feline” esophagus, in eosinophilicesophagitis, 1:433–437

Fentanyl, with midazolam, for sedationin colonoscopy, versus propofol,1:425–432

Ferritin, normal levels, in patients ho-mozygote for hemochromatosisgene, 1:388–391

Fistulae, esophageal perforation with,endoscopic clip application forclosure of, 1:44–50

Five-year interval, between colonosco-pies, for patients with familyhistory of colorectal cancer,1:310–314

Flexible sigmoidoscopycost-effectiveness of, 1:404–413diminutive adenomas found in, predic-

tive value of, 1:195–201predictors of advanced proximal neoplasia

in, 1:103–110Fluorescence in situ hybridiza-

tion (FISH), of epidermalgrowth factor receptor expression,in gastric cancer, 1:439–443

Fluoxetinefor irritable bowel syndrome, 1:156,

219–228and rectal sensitivity, 1:219–228

Fluticasone, for eosinophilic esophagitis,f:436

Follow-up, in evidence-based studies, 1:59Follow-up colonoscopy, findings in

flexible sigmoidoscopy indicating,1:103–110

Fracture risk, in ulcerative colitis,1:465–473

Fulminant hepatic failure, mush-room-induced, recovery fromwithout liver transplantation,1:392–396

Functional dyspepsiagastric accommodation and emptying in,

evaluation of, 1:264–272gastric mucosal mast cells in, 1:363–369

Fundoplicationcost-effectiveness of, 1:84–85, 328–332gastric accommodation and emptying

after, evaluation of, 1:264–272for GERD, versus medical therapy, 1:81–

88, 328–332laparoscopic, 1:82, 84, 328–332safety and side effects of, 1:84

Gastric accommodation, in patientswith upper gastrointestinal symp-toms, evaluation of, 1:264–272

Gastric acid production, exerciseand, 1:346–347

Gastric cancerepidermal growth factor receptor expres-

sion in, 1:438–445exercise effects in, 1:348Helicobacter pylori infection and, 1:416mortality in, 1:438

Gastric emptyingexercise and, 1:346–347in irritable bowel syndrome, clonidine

and, 1:111–121in patients with upper gastrointestinal

symptoms, evaluation of, 1:264–272

Gastric lavage, for mushroom-inducedhepatitis, 1:394–395

Gastric mucosal injury, NSAID-induced

COX-2 inhibitor effects versus conven-tional NSAIDS, 1:57–63

evidence-based studies of, 1:57–63sucralfate therapy, 1:51–56

Gastric mucosal mast cells, in func-tional dyspepsia, 1:363–369

Gastric volumes, measurement of,1:113–114

Gastroenterologistsacademic, challenges of, 1:153–155collaboration with psychologists, in irri-

table bowel syndrome treatment,1:423–424, 446–452

Gastroenterology residents, knowl-edge base evaluation of, versusfaculty assessment, 1:64–68

Gastroesophageal reflux disease(GERD)

convenience of therapies for, 1:84

costs of therapies for, 1:84–85, 328–332

efficacy of therapies for healing,1:81–82

endoscopic antireflux procedures for,1:85–86

exercise effects in, 1:345–346laparoscopic Nissen fundoplication for,

1:82, 84, 328–332laryngeal signs and symptoms in,

1:333–344medical versus invasive therapy for,

1:81–88, 328–332prevention of complications in, 1:83–84and risk of esophageal cancer, 1:81,

83–84safety and side effects of therapies for,

1:84Gastrointestinal bleeding

exercise and, 1:351–352NSAID-induced

COX-2 inhibitor effects versus conven-tional NSAIDs, 1:57–63

evidence-based studies of, 1:57–63sucralfate therapy for, 1:51–56

with stromal cell tumors, 1:419Gastrointestinal clinical research,

2002-2003, review of, 1:415–420Gastrointestinal disease

exercise effects in, 1:345–355natural history of, evidence-based studies

of, 1:229–236Gastrointestinal motility

exercise and, 1:349–350impaired, in postoperative ileus,

1:71–80Gastrointestinal practices, codes

and reimbursements for, updateon, 1:237–239

Gastrointestinal transitexercise and, 1:349–350in irritable bowel syndrome, clonidine

and, 1:111–121measurement of, 1:113

G-codes, 1:237–239Gene amplification, in gastric cancer,

1:438–445GERD. See Gastroesophageal re-

flux disease (GERD)Ghrelin, in postoperative ileus, 1:72Globus sensation, GERD and, 1:333�-Glutamyl transpeptidase, in auto-

immune pancreatitis, 1:454,455, 457, 460

Gluten sensitivityfluctuating transglutaminase autoanti-

bodies in, 1:356–362in North America, 1:19–27

Glycopyrrolate, with endoscopic clipclosure of esophageal perforation,1:46–47, 49


Gold standard tests, comparison ofnew tests with, 1:138–139

Grants, for academic physician-scientists,1:153–155

Granulocyte apheresis, for ulcerativecolitis, 1:28–35, 417

Groupe d’Etude et de Traitementdu Carcinome Hepatocel-lulaire (GETCHC), hepato-cellular carcinoma classificationof, 1:11

Halothane, and postoperative ileus,1:73

Health care delivery, integration ofservices in, 1:145–151

Helicobacter pylori infectionantimicrobial susceptibility testing in,

1:273–278eradication, for ulcer bleeding prevention

in ongoing NSAID therapy,1:416

and gastric cancer risk, 1:416Hemochromatosis, hereditary

and hepatocellular carcinoma, 1:246–248, 279–284

patients homozygote for gene for, normalferritin levels in, 1:388–391

Hemorrhagic colitis, antibiotic-associated, Klebsiella oxytocain, 1:370–376

Hepatic artery embolization, forhepatocellular carcinoma, 1:15–16, 18

Hepatic failure, fulminant, mush-room-induced, 1:392–396

Hepatitis, mushroom-induced, recoveryfrom without liver transplanta-tion, 1:392–396

Hepatitis B infectionchronic, treatment of, 1:418and hepatocellular carcinoma, 1:10–11,

17prevention of, 1:17, 18treatment of, 1:17

Hepatitis B vaccine, 1:17, 18Hepatitis C infection

chronic, treatment of, 1:418and hepatocellular carcinoma, 1:10–11,

17treatment of, 1:17

Hepatocellular carcinomachemoembolization for, 1:15–16, 18classification of, 1:11incidence of, 1:10iron and HFE mutations in, 1:246–248,

279–284liver transplantation for, 1:13, 17local ablative therapies for, 1:13–15,

17–18

natural history of, 1:12pathogenesis of, 1:10–11prevention of, 1:17, 18prognostic factors in, 1:11–12radiation therapy for, 1:16–17recurrence of, 1:13risk factors for, 1:10staging of, 1:11, 12surgical resection for, 1:12–13, 17survival of patients with, 1:18systemic therapies for, 1:16, 17treatment of, 1:10–18

Hepatolithiasis, prostaglandin E recep-tors in, 1:285–296

Hepatologists, academic, challenges of,1:153–155

Hereditary hemochromatosisand hepatocellular carcinoma, 1:246–

248, 279–284patients homozygote for gene for, normal

ferritin levels in, 1:388–391HFE mutations

and hepatocellular carcinoma, 1:246–248, 279–284

homozygosity for, normal ferritin levelsin patients with, 1:388–391

High-grade dysplasia, Barrett’sesophagus with, endoluminaltherapy for, 1:241–245, 258–263

Histamine H1-receptor antago-nists, for eosinophilic esophagi-tis, 1:433, 434, 436

Histamine H2-receptor antago-nists

for eosinophilic esophagitis, 1:433, 434,436

and exercise-induced reflux, 1:346for GERD, 1:81–82, 84, 334, 341–342,

346nocturnal use of, 1:334, 341–342safety and side effects of, 1:84

Hoarseness, in GERD, 1:333Hormonal therapy, for hepatocellular

carcinoma, 1:16, 18Hot saline injection, for hepatocellu-

lar carcinoma, 1:14Hydrocortisone, with infliximab, for

Crohn’s disease, 1:417Hypokalemia, in postoperative ileus,

1:73Hypopharyngeal pH monitoring,

in GERD patients with laryngealcomplaints, 1:335, 338–340

Idiopathic duct-centric chronicpancreatitis (IDCP), 1:129,132–134, 421

Idiopathic eosinophilic esophagi-tis (IEE), endoscopy in,1:433–437

Idiopathic tumefactive chronicpancreatitis, 1:129–135, 421

Ileitis, ulcerative, drug-induced,1:160–169

Ileo-colonoscopy, drug-induced ulcer-ative ileitis encountered in,1:160–169

Ileus, postoperativeagents for

with possible therapeutic benefit andlow risk of harm in, 1:75–76

with potential for harm and lack ofbenefit in, 1:76–77

with probable therapeutic benefits in,1:74–75

anesthesia and, 1:72, 73, 74definition of, 1:71etiologies of and interventions for,

1:71–80laparoscopic procedure and reduction of,

1:73, 74multimodal therapy for, 1:75pathophysiology of, 1:71–73potential, unevaluated therapies for,

1:77preoperative psychological preparation

for, 1:76prevention of, 1:71treatment of, 1:71, 73–77

Imatinib, for stromal cell tumors,1:418–419

Imipramine, for irritable bowel syn-drome, 1:155–157

Immunoglobulin G, in autoimmunepancreatitis, 1:422, 453, 454,460, 462–463

Immunosuppressive therapyfor eosinophilic esophagitis, 1:433with infliximab, for Crohn’s disease,

1:417Immunotherapy, for hepatocellular

carcinoma, 1:16Indebtedness, management by aca-

demic physician-scientists,1:153–155

Inflammatory bowel disease. Seealso Crohn’s disease (CD);Ulcerative colitis (UC)

bone health in, 1:348–349, 465–473exercise effects in, 1:348–349novel therapies for, 1:416–417susceptibility gene for, 1:5–9

Inflammatory response, and postop-erative ileus, 1:72

Infliximabfor Crohn’s disease, 1:416–417

CARD15 gene mutations and responseto, 1:7–8

Insulin resistance, in non-alcoholicfatty liver disease, pioglitazoneand, 1:384–387


Integration, of digestive health careservices, 1:145–151

Integrins, alpha-4, therapy targeting inCrohn’s disease, 1:417

Intention-to-treat analysis, 1:59Interferon

for hepatitis B infection, 1:17for hepatitis C infection, 1:17for hepatocellular carcinoma, 1:16

Interleukin 1, in postoperative ileus,1:72

Interleukin 2, for hepatocellular carci-noma, 1:16

Interleukin 6, in postoperative ileus,1:72

Interstitial laser coagulation(ILC), for hepatocellular carci-noma, 1:15

Intraductal ultrasonography(IDUS), in autoimmune pancre-atitis, 1:454, 456, 457, 459, 460

In-Training Examination (ITE),versus faculty assessment of resi-dents, 1:64–68

Intramucosal carcinoma (IMCA),with Barrett’s esophagus, endolu-minal therapy for, 1:241–245,252–257

Ironin hepatic carcinogenesis, 1:246–248,

279–284normal levels, in patients homozygote for

hemochromatosis gene, 1:388–391

Irritable bowel syndrome (IBS)clinical practice guidelines for, evidence-

based approach to, 1:322–327collaborative medical-psychological treat-

ment for, 1:423–424, 446–452diarrhea-predominant, clonidine for,

1:111–121prevalence of, 1:111primary symptoms of, 1:111rectal sensitivity in, fluoxetine and,

1:219–228selective serotonin reuptake inhibitors

for, 1:155–159, 219–228

Jaundicecholestatic, as paraneoplastic manifesta-

tion of prostate cancer, 1:480–483

obstructive, in tumefactive chronic pan-creatitis, 1:129, 133–134

Jejunal feeding, with endoscopic clipclosure of esophageal perforation,1:46–47, 49

Klebsiella oxytoca, in antibiotic-asso-ciated hemorrhagic colitis,1:370–376

Knowledge base evaluation, of resi-dents, versus faculty assessments,1:64–68

K-ras, in colorectal cancer, fecal testingfor, 1:377–383

Lactulose, for mushroom-induced hepa-titis, 1:394

Lansoprazole, for ulcer bleeding pre-vention, with ongoing NSAIDtherapy, 1:416

Laparoscopic proceduresfor fundoplication, 1:82, 84, 328–332and reduction of postoperative ileus,

1:73, 74Laryngeal cancer, GERD and, 1:333Laryngeal signs and symptoms,

in GERDcause and effect association of, 1:333–

344diagnostic tests for, 1:335–338laryngoscopy in, 1:335–338pathophysiology of, 1:334–335pH monitoring in, 1:333–335, 338–

340therapy for, 1:334, 340–342

Laryngitis, reflux, in GERD, 1:333–344

Laryngopharyngeal reflux, 1:333–344

Laryngoscopyin GERD patients with laryngeal com-

plaints, 1:334, 335–338subjectivity of, 1:337–338

Lavage, nasogastric, for mushroom-induced hepatitis, 1:394–395

Laxatives, for postoperative ileus, 1:76Length of stay analysis, of inte-

grated digestive health care ser-vices, 1:146–147

Leukocyte adsorptive apheresis,for ulcerative colitis, 1:28–35,417

Lifestyle modification, for GERD,1:81–82

Likelihood ratios, 1:140–142Lipiodol, in hepatocellular carcinoma

therapy, 1:15, 17Lipolytic activity, in chronic pancreati-

tis and pancreatic cancer, 1:397–403

Liver biopsyin autoimmune pancreatitis, 1:454, 457in primary biliary cirrhosis, 1:89–95

Liver diseaseexercise and, 1:352–353pruritus in, 1:249–251, 297–302

Liver transplantationfor hepatocellular carcinoma, 1:13, 17

living donor, endoscopic management ofbiliary complications in donorsfor, 1:183–188

for mushroom-induced hepatitis, avoid-ance of, 1:392–396

Living donor liver transplanta-tion (LDLT), biliary complica-tions in donors for, endoscopicmanagement of, 1:183–188

Loan Repayment Program, 1:153Lymphokine-activated natural

killer cells, for hepatocellularcarcinoma, 1:16

Lymphoplasmacytic sclerosingpancreatitis, 1:129, 132–134, 421

Magnetic resonance imaging, inautoimmune pancreatitis, 1:454,459

Manometry, combined with multichan-nel intraluminal impedance, foresophageal function testing,1:174–182

Mast cells, gastric mucosal, in functionaldyspepsia, 1:363–369

Maternal age, and pediatric-onsetCrohn’s disease, 1:303–309

Medicare, codes and reimbursements for,update on, 1:237–239

Mercaptopurine, with infliximab, forCrohn’s disease, 1:417

Mesalaminefor Crohn’s disease, versus budesonide,

1:122–128delivery systems for, 1:3–4, 36–43once daily versus conventional dosing of,

1:170–173optimal dosing of, 1:3–4, 36–43pellet preparation of, 1:3–4, 36–43for ulcerative colitis, 1:3–4, 36–43,

170–173Methotrexate, with infliximab, for

Crohn’s disease, 1:417Methylene blue-aided chromoen-

doscopy, in colorectal cancer,1:416

Methylnaltrexone, for postoperativeileus, 1:75

Metoclopramide, for postoperative il-eus, lack of benefit and potentialfor harm with, 1:76

Metronidazole, for Helicobacter pyloriinfection, microbial susceptibilityto, 1:273–278

Microsatellite instability (MSI)-positive colorectal can-cers

cigarette smoking and, 1:208–209molecular tests for, 1:377–383


Microwave coagulation therapy(MCT), for hepatocellular carci-noma, 1:15

Midazolam/fentanyl, for sedation incolonoscopy, versus propofol,1:425–432

Migrating motor complex (MMC),in postoperative ileus, 1:71–73

Milk thistle, for mushroom-inducedhepatitis, 1:394–395

Mind-body medicine, for irritablebowel syndrome, 1:423–424,446–452

Molecular tests, fecal, for colorectalcancer, 1:377–383

Monocyte/macrophage apheresis,for ulcerative colitis, 1:28–35,417

Motility, gastrointestinalexercise and, 1:349–350impaired, in postoperative ileus,

1:71–80MUCOSA Trial, 1:60–61Mucosal injury, gastric, NSAID-

inducedCOX-2 inhibitor effects versus conven-

tional NSAIDS, 1:57–63evidence-based studies of, 1:57–63sucralfate therapy, 1:51–56

Mucosal mast cells, gastric, infunctional dyspepsia, 1:363–369

Mucosal resection, endoscopic,with photodynamic therapy, forBarrett’s esophagus, 1:241–245,252–257

Multichannel intraluminal imped-ance

combined with manometry, for esopha-geal function testing, 1:174–182

for laryngeal complaints in GERD, 1:335Mushroom-induced hepatitis

clinical course of, 1:393–394recovery from without liver transplanta-

tion, 1:392–396therapy for, 1:394

N-acetylcysteine, for mushroom-in-duced hepatitis, 1:394–396

Naloxone, for postoperative ileus, 1:75Naproxen

gastric effects of, versus rofecoxib,1:57–63

ulcer bleeding with ongoing therapy,prevention of, 1:416

Nasobiliary drainage, endoscopic, indonors for living donor livertransplantation, 1:183–188

Nasogastric decompression(NGC), for postoperative ileus,lack of benefit and potential forharm with, 1:76

Nasogastric lavage, for mushroom-induced hepatitis, 1:394–395

Natalizumab, for Crohn’s disease, 1:417National Institutes of Health, sup-

port for academic physician-scien-tists, 1:153–155

Natural history, of gastrointestinaldisease, evidence-based studies of,1:229–236

Necrotizing pancreatitismortality in, 1:315nutrition in management of, 1:315–321

Negative predictive value, of diag-nostic tests, 1:140–141

Neostigmine, for postoperative ileus,1:76

Nissen fundoplicationfor GERD, versus medical therapy, 1:81–

88, 328–332laparoscopic, 1:82, 84, 328–332

Nitric oxide, in postoperative ileus,1:72

Nitric oxide inhibitors, for hepato-cellular carcinoma prevention,1:17

Nitrous oxide, and postoperative ileus,1:73

Nocturnal acid breakthrough(NAB), 1:341

NOD2 (CARD15) gene mutationsin Crohn’s disease, 1:5–9discovery of, impact of, 1:5influence on clinical presentation and

natural history, 1:6–7risk conferred by inheritance of, 1:5–6screening for, 1:8and treatment response, 1:7–8

Non-alcoholic fatty liver disease(NAFLD), biochemical indicesin, pioglitazone and, 1:384–387

Nonsteroidal anti-inflammatorydrugs (NSAIDs)

for colorectal cancer prevention, 1:415–416

COX-2-selective versus conventional,1:57–63

gastric injury induced byevidence-based studies of, 1:57–63sucralfate therapy for, 1:51–56

for postoperative ileus, 1:74–75and reduced incidence of adenomas,

1:310–314, 415–416ulcer bleeding with ongoing, prevention

of, 1:416ulcerative ileitis induced by, 1:160–169

North America, celiac disease in, trendsin identification and clinical fea-tures, 1:19–27

Number needed to treat (NNT), inevidence-based studies, 1:60–61

Nurse-administered sedation, forcolonoscopy, 1:425–432

Nutrition, in management of necrotizingpancreatitis, 1:315–321

Obese patients, non-alcoholic fattyliver disease in, pioglitazone for,1:384–387

Obstructive jaundice, in tumefactivechronic pancreatitis, 1:129, 133–134

Octreotide, for hepatocellular carcinoma,1:16

Okuda classification, of hepatocellu-lar carcinoma, 1:11

Olmsted County, Minnesotaceliac disease in, trends in identification

and clinical features, 1:19–27ulcerative colitis in, fracture risk with,

1:465–473Oltipraz, for hepatocellular carcinoma

prevention, 1:17Omeprazole

for exercise-induced reflux, 1:346for ulcer bleeding prevention, with ongo-

ing NSAID therapy, 1:416Opiates/opioids

endogenous, in pruritus, 1:249–251and postoperative ileus, 1:72, 75

Orthotopic liver transplantation(OLT), for hepatocellular carci-noma, 1:13, 17

Osteopenia/osteoporosis, in inflam-matory bowel disease

exercise effects on, 1:348–349and fracture risk, 1:465–473

Outcome criteria, for evidence-basedstudies, 1:231

p53 tumor suppressor gene muta-tions

in colorectal cancer, fecal testing for,1:377–383

in hepatocellular carcinoma, 1:10P value, 1:61Pancreatic biopsy, in autoimmune

pancreatitis, 1:454, 457Pancreatic cancer

rapid endoscopic secretin stimulation testfor, 1:397–403

tumefactive chronic pancreatitis and,1:129–135

Pancreatic function testsin autoimmune pancreatitis, 1:457, 459endoscopic, 1:189–194

rapid secretin stimulation, 1:397–403Pancreatitis

alcohol-induced tumefactive chronic,1:129–135


autoimmune, 1:133–134biliary system involvement in, 1:421,

453–464simplification and consistency in field

of, 1:421–422chronic

endoscopic pancreatic function test for,1:189–194

rapid endoscopic secretin stimulationtest for, 1:397–403

chronic inflammatory, 1:133idiopathic duct-centric chronic, 1:129,

132–134idiopathic tumefactive chronic, 1:129–

135, 421lymphoplasmacytic sclerosing, 1:129,

132–134, 421with narrowing pancreatic duct, 1:459necrotizing, nutrition in management of,

1:315–321non-alcohol-induced duct destructive,

1:133non-sclerosing, 1:133sclerosing, 1:133, 421, 459–460terminology for, 1:129, 133, 421

Paraneoplastic syndrome, in pros-tate cancer, cholestatic jaundiceas, 1:480–483

Parenteral feeding, in necrotizingpancreatitis, 1:315–321

Paroxetine, for irritable bowel syn-drome, 1:156–157, 219

Pediatric-onset Crohn’s disease,sex-specific risks for, 1:303–309

Peginterferons, with ribavirin, forchronic hepatitis C infection,1:418

Pellet preparation, of mesalamine,1:3–4, 36–43

Penicillin, hemorrhagic colitis associatedwith, Klebsiella oxytoca in,1:370–376

Penicillin G, for mushroom-inducedhepatitis, 1:394–396

Pepsin, and laryngeal injury in GERD,1:334–335

Peptic ulcer diseaseantimicrobial susceptibility testing in,

1:273–278effects of COX-2 inhibitors versus con-

ventional NSAIDs on, 1:57–63exercise and, 1:347–348in GERD, prevention of, 1:83

Percutaneous alcohol injection(PEI), for hepatocellular carci-noma, 1:13–14, 17–18

Percutaneous transhepatic biliarydrainage (PTBD), for auto-immune pancreatitis, 1:454, 457

Percutaneous transhepaticcholangiography, in auto-immune pancreatitis, 1:454,457, 458

Peroxisome proliferator-activatedreceptors, in non-alcoholicfatty liver disease, 1:386–387

pH monitoringambulatory esophageal and pharyngeal,

1:333, 338–340in GERD patients with laryngeal

complaints, 1:333–335, 338–340

Pharyngeal pH monitoring, inGERD patients with laryngealcomplaints, 1:335, 338–340

Phospholipase A2, secretory-typegroup IIA, in cholangitis,1:285–296

Photodynamic therapy (PDT), withendoscopic mucosal resection, forBarrett’s esophagus, 1:241–245,252–257

Physical activity (exercise), andgastrointestinal function and dis-ease, 1:345–355

Piezoelectric technology, for pruri-tus assessment, 1:250

Pioglitazone, for non-alcoholic fattyliver disease, 1:384–387

Polyprenoic acid, for prevention ofsecond primary tumors, in hepa-tocellular carcinoma, 1:17

Polyps, colorectalcolorectal cancer risk factors in patients

with, 1:415diminutive, predictive value of, 1:195–

201family history of, as indication for cancer

screening, 1:69–70, 96–102five-year interval in screening for, in pa-

tients with family history of can-cer, 1:310–314

NSAIDs and reduced incidence of,1:310–314, 415–416

as predictor of advanced proximal neo-plasia, 1:103–110

Portal hypertension, ascites in, evi-dence-based studies of manage-ment of, 1:474–479

Positive predictive value, of diag-nostic tests, 1:140–141

Postfundoplication syndromes,gastric accommodation and emp-tying in, evaluation of, 1:264–272

Postmenopausal women, cigarettesmoking and risk of colorectalcancer in, 1:202–210

Postoperative ileusagents for

with possible therapeutic benefit andlow risk of harm in, 1:75–76

with potential for harm and lack ofbenefit in, 1:76–77

with probable therapeutic benefits in,1:74–75

anesthesia and, 1:72, 73, 74definition of, 1:71etiologies of and interventions for,

1:71–80laparoscopic procedure and reduction of,

1:73, 74multimodal therapy for, 1:75pathophysiology of, 1:71–73potential, unevaluated therapies for,

1:77preoperative psychological preparation

for, 1:76prevention of, 1:71treatment of, 1:71, 73–77

Posttest probability, 1:141PREDICT Trial, 1:195–201Prednisolone, for autoimmune pancre-

atitis, 1:454, 457–459Prednisone, for eosinophilic esophagitis,

1:434Pretreatment antimicrobial sus-

ceptibility testing, in Helico-bacter pylori infection, 1:273–278

Primary biliary cirrhosis (PBC)common signs and symptoms of, 1:89liver biopsy for diagnosis of, 1:89–95pancreatitis with, 1:421–422, 453pruritus in, 1:249–251, 297–302

Primary sclerosing cholangitis,pancreatitis with, 1:421–422,453, 459, 462–463

Propofol, for sedation in colonoscopy,versus midazolam/fentanyl,1:425–432

Prostaglandin E receptors, in hepa-tolithiasis and cholangitis,1:285–296

Prostate, Lung, Colorectal, andOvarian (PLCO) CancerScreening Trial, 1:103–110

Prostate cancer, cholestatic jaundice asparaneoplastic manifestation of,1:480–483

Proton beam radiation therapy,for hepatocellular carcinoma,1:17

Proton pump inhibitors (PPIs)cost of, 1:85for eosinophilic esophagitis, 1:433, 434,

435–436and exercise-induced reflux, 1:346for GERD, 1:82, 84, 328, 330, 333–

334, 341–342, 346


safety and side effects of, 1:84for ulcer bleeding prevention, with ongo-

ing NSAID therapy, 1:416Pruritus

natural history of, 1:297–302prevalence of, 1:298in primary biliary cirrhosis, 1:249–251,

297–302in prostate cancer, 1:480–483refractory, rifampin for, 1:297–302risk factors for, 1:299symptomatic, management of, 1:29821st-century study of, 1:249–251

Psychologists, collaboration with gas-troenterologists, in irritablebowel syndrome treatment,1:423–424, 446–452

Quality of life, in Crohn’s disease, me-salamine versus budesonide effectson, 1:122–128

Radiation therapy, for hepatocellularcarcinoma, 1:16–17

Radiofrequency ablation (RFA),for hepatocellular carcinoma,1:13–15, 17–18

Radioisotope therapy, for hepatocel-lular carcinoma, 1:17

Randomized clinical trials,1:57–59

Receptor tyrosine kinases(RTKs), expression, in gastriccancer, 1:438–445

Rectal sensitivity, in irritable bowelsyndrome, fluoxetine and,1:219–228

Reflux disease. See Gastroesopha-geal reflux disease(GERD)

Reflux finding score (RFS), 1:336–337, 340

Reflux laryngitis, in GERD, 1:333–344

Reimbursements, update on, 1:237–239

Relative risk reduction (RRR), inevidence-based studies, 1:60–61

Renal cell carcinoma, cholestasiswith, 1:480

Research2002-2003, review of, 1:415–420funding and management of, 1:153–155

Residents, knowledge base evaluationof, versus faculty assessments,1:64–68

Review bias, 1:138Rheumatoid factor (RF), in autoim-

mune pancreatitis, 1:453, 454,455, 459–460

Ribavirin, with peginterferons, forchronic hepatitis C infection,1:418

Rifampin, for refractory pruritus,1:297–302

Rofecoxib, gastric effects of, versusnaproxen, 1:57–63

Rosiglitazone, for non-alcoholic fattyliver disease, 1:386

Rumination syndrome, gastric ac-commodation and emptying in,evaluation of, 1:264–272

S-adenosylmethionine, for hepatocel-lular carcinoma prevention, 1:17

Saline injection, hot, for hepatocellularcarcinoma, 1:14

Scintigraphy, of gastric emptying, inpatients with dyspepsia, 1:264–272

Sclerosing pancreatitis, 1:133, 421,459–460

Scratching activity monitoringsystem (SAMS), 1:250

Screening colonoscopycost-effectiveness of, 1:404–413family history of adenomas as indication

for, 1:69–70, 96–102findings in flexible sigmoidoscopy indi-

cating, 1:103–110five-year interval between, in patients

with family history of colorectalcancer, 1:310–314

Secretin stimulation test, rapid en-doscopic, for chronic pancreatitisand pancreatic cancer, 1:397–403

Secretory-type group IIA phos-pholipase A2 (sPLA2-IIA),in cholangitis, 1:285–296

Sedation, for colonoscopy, propofol versusmidazolam/fentanyl, 1:425–432

Selective serotonin reuptake in-hibitors (SSRIs)

and colonic sensorimotor function,1:211–218

gender-specific responses to, 1:157for irritable bowel syndrome, 1:155–

159, 219–228Sensitivity, of diagnostic tests, 1:140–

141Sensorimotor function, colonic

effects of venlafaxine, buspirone, andplacebo on, 1:211–218

selective serotonin reuptake inhibitorsand, 1:155–159

Sex-specific risks, for pediatric-onsetCrohn’s disease, 1:303–309

Sham feeding, in postoperative ileus,1:75

Silybum marianum, for mushroom-induced hepatitis, 1:394–395

Single photon emission computedtomography (SPECT)

of gastric accommodation, in patientswith dyspepsia, 1:264–272

for gastric volume measurement, 1:113–114

Sjogren’s syndrome, pancreatitiswith, 1:421, 453

Small-bowel ulcerations, drug-in-duced, encountered in ileo-colonoscopy, 1:160–169

Smoking, and risk of colorectal cancer,in postmenopausal women,1:202–210

Somatostatinfor hepatocellular carcinoma, 1:16for postoperative ileus, 1:77

Sore throat, in GERD, 1:333Specialized intestinal metaplasia

(SIM), esophagealclassification of, 1:241endoluminal therapy for, 1:241–245

Specificity, of diagnostic tests, 1:140–141

Stauffer’s syndrome, 1:480Stenting, biliary, in donors for living

donor liver transplantation,1:183–188

Steroid-dependent Crohn’s dis-ease, mesalamine versus budes-onide in, 1:122–128

Stool tests, multiple molecular, for colo-rectal cancer detection, 1:377–383

Stress response, and postoperativeileus, 1:73

Stromal cell tumors, imatinib for,1:418–419

Substance P, in postoperative ileus,1:72

Sucralfate therapy, for NSAID-in-duced gastropathy, 1:51–56

Sulfasalazine, for mesalamine delivery,1:3, 36

Surgical resectionendoscopic mucosal, for Barrett’s esopha-

gus, 1:241–245, 252–257for hepatocellular carcinoma, 1:12–13,

17for idiopathic tumefactive chronic pan-

creatitis, 1:129–135Sympathetic activity, in postoperative

ileus, 1:72

Tamoxifen, for hepatocellular carcinoma,1:16

Thermal ablative therapy, for Bar-rett’s esophagus, 1:241–245

Thiazolidinediones, for non-alcoholicfatty liver disease, 1:384–387


Tobacco use, and risk of colorectal can-cer, in postmenopausal women,1:202–210

Total parenteral nutrition (TPN),in necrotizing pancreatitis,1:315–321

Transarterial chemoembolization(TACE), for hepatocellular car-cinoma, 1:15–16, 18

Transforming growth factor �, inchronic pancreatitis, 1:401

Transglutaminase autoantibodies,fluctuating, and histologic featuresof celiac disease, 1:356–362

Tricyclic antidepressantsgender-specific responses to, 1:157for irritable bowel syndrome, 1:155–

159, 219, 225–226Troglitazone, for non-alcoholic fatty

liver disease, 1:386Trypsin, and laryngeal injury in GERD,

1:334Tumefactive chronic pancreatitis

alcohol-induced, 1:129–135, 421clinical classification of, 1:130clinical presentation of, 1:130histology of, 1:130, 1:132–134idiopathic, 1:129–135, 421

Tumor necrosis factor-�, in inflamma-tory bowel disease, therapy targeting,1:416–417

Ulcer(s)antimicrobial susceptibility testing in

treatment of, 1:273–278bleeding, with ongoing NSAID therapy,

prevention of, 1:416drug-induced, encountered in ileo-

colonoscopy, 1:160–169

effects of COX-2 inhibitors versus con-ventional NSAIDs on, 1:57–63

exercise and, 1:347–348in GERD, prevention of, 1:83

Ulcerative colitis (UC)exercise effects in, 1:348–349fracture risk in, 1:465–473leukocyte adsorptive apheresis for, 1:28–

35, 417mesalamine for

once daily versus conventional dosingof, 1:170–173

optimal dosing and delivery systemsof, 1:3–4, 36–43

pancreatitis with, 1:453Ulcerative ileitis, drug-induced

clinical and endoscopic follow-up in,1:162–163

versus Crohn’s disease, 1:166–167encountered in ileo-colonoscopy, 1:160–

169endoscopic and histopathologic features

of, 1:162medications implicated in, 1:162–163population at risk for, 1:165–166response to finding, 1:167

Ultrasoundin autoimmune pancreatitis, 1:454, 456,

457, 459, 460endoscopic, of Barrett’s esophagus,

1:242–244University of Virginia’s Digestive

Health Service Center(DHSC), 1:145–151

Upper gastrointestinal symptoms,gastric accommodation and emp-tying in patients with, evaluationof, 1:264–272

Ursodeoxycholic acid (UDCA), forpruritus, 1:249–251, 297–302

Vagal dysfunction, evaluation of,1:264–272

Vasoactive intestinal peptide(VIP), in postoperative ileus,1:72

Venlafaxineand colonic sensorimotor function,

1:211–218for irritable bowel syndrome, 1:156

Verification bias, 1:139VIGOR Trial, 1:57–63Virtual colonoscopy

accuracy of, quantification of, 1:142evidence-based studies of, 1:136–144versus gold standard test, 1:138–139necessity of, 1:136–138

Visceral sensitivity, in irritable bowelsyndrome, fluoxetine and,1:219–228

Vitamin K, for mushroom-induced hepa-titis, 1:394–395

Women, postmenopausal, cigarettesmoking and risk of colorectalcancer in, 1:202–210

Year in review (2002-2003),1:415–420

Yttrium 90 (90Y) isotopes, in hepa-tocellular carcinoma therapy, 1:17

ZD1839 (Iressa), potential use in gas-tric cancer, 1:439, 444

Zinc, for mushroom-induced hepatitis,1:394


Documents

Subject index